Showing results (1-10 of 327) with videos related to
Sort By:
Pageof 33
British Journal of Cancer|May 20, 2017
Hallmarks of response to immune checkpoint blockadeAlexandria P Cogdill, Miles C Andrews, Jennifer A WargoClinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2016
Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?Alexandria P Cogdill, Peter A Prieto, Alexandre Reuben, et al.Journal for Immunotherapy of Cancer|February 28, 2017
Immunotherapy resistance: the answers lie ahead - not in front - of usMiles C Andrews, Jennifer A WargoAnnals of Surgical Oncology|March 4, 2018
The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid MalignanciesEmily Z Keung, Esosa U Ukponmwan, Alexandria P Cogdill, et al.Trends in Immunology|November 6, 2018
The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer TherapyAlexandria P Cogdill, Pierre Olivier Gaudreau, Reetakshi Arora, et al.Surgery|November 19, 2013
Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancerViswanath Gunda, Alexandria P Cogdill, Maria J Bernasconi, et al.Frontiers in Immunology|May 22, 2018
Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer TherapyMiles C Andrews, Alexandre Reuben, Vancheswaran Gopalakrishnan, et al.Cell|August 15, 2017
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeSpencer C Wei, Jacob H Levine, Alexandria P Cogdill, et al.Proceedings of the National Academy of Sciences of the United States of America|October 23, 2019
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapiesSpencer C Wei, Nana-Ama A S Anang, Roshan Sharma, et al.Surgery|July 10, 2012
Targeting the MAGE A3 antigen in pancreatic cancerAlexandria P Cogdill, Dennie T Frederick, Zachary A Cooper, et al.Pageof 33